No Washout Period Required When Transitioning from Bisphosphonates to Evenity
You can transition directly from bisphosphonates to romosozumab (Evenity) without a washout period. Neither the FDA label nor current guidelines specify any required washout period, and clinical trial data demonstrate safe and effective transitions without intervening drug-free intervals 1.
Evidence Supporting Direct Transition
FDA Labeling Guidance
The FDA-approved prescribing information for Evenity does not mandate or recommend any washout period when switching from bisphosphonates 1. The drug label addresses various clinical scenarios but is notably silent on requiring treatment-free intervals during transitions from other osteoporosis medications.
Clinical Trial Evidence
Multiple high-quality studies have evaluated direct transitions from bisphosphonates to romosozumab:
The STRUCTURE trial (2017) enrolled 436 postmenopausal women who had taken oral bisphosphonates for at least 3 years (including alendronate in the year before screening) and directly transitioned them to either romosozumab or teriparatide without any washout period 2. Romosozumab demonstrated superior efficacy with a 2.6% increase in total hip BMD compared to -0.6% with teriparatide (difference 3.2%, p<0.0001).
Recent real-world data (2025) from a multicenter case-control study of 389 patients who switched from bisphosphonates to romosozumab, denosumab, or teriparatide showed that romosozumab produced the most substantial BMD improvements without any washout period 3. After 12 months, romosozumab increased lumbar spine BMD by 11.4% (versus 6.3% with denosumab and 5.9% with teriparatide, both p<0.001).
Japanese cohort study (2021) specifically compared patients switching from bisphosphonates to romosozumab versus treatment-naïve patients starting romosozumab 4. Both groups showed significant BMD increases without washout periods, though the treatment-naïve group showed slightly greater responses.
Clinical Rationale
Why No Washout Is Needed
Romosozumab's dual mechanism of action (stimulating bone formation while inhibiting resorption) works effectively even in the presence of residual bisphosphonate effects 3. The drug demonstrates a unique ability to:
- Rapidly increase bone formation markers despite prior bisphosphonate suppression
- Simultaneously decrease bone resorption markers
- Produce greater BMD gains than other anabolic agents in bisphosphonate-pretreated patients
Practical Considerations
Prior bisphosphonate use does attenuate romosozumab's bone-forming effects compared to treatment-naïve patients 4, 2, but this does not justify delaying treatment with a washout period. The clinical benefits of immediate transition outweigh any theoretical advantages of waiting:
- Romosozumab still produces clinically meaningful BMD increases in bisphosphonate-pretreated patients
- Delaying treatment leaves patients at continued fracture risk
- The 12-month treatment window for romosozumab is limited, making prompt initiation important
Treatment Algorithm
When transitioning from bisphosphonates to romosozumab:
- Verify appropriate indication: Confirm patient is at very high fracture risk per ACP guidelines 5
- Check contraindications: Ensure no cardiovascular contraindications, severe renal impairment without adequate monitoring, or pre-existing hypocalcemia 1
- Optimize calcium/vitamin D: Ensure adequate supplementation before starting romosozumab 1
- Initiate romosozumab immediately: Begin 210 mg monthly subcutaneous injections without waiting
- Plan sequential therapy: After 12 months of romosozumab, transition to an antiresorptive agent (denosumab or bisphosphonate) to maintain gains 5
Important Caveats
Monitor calcium levels closely in patients with severe renal impairment (eGFR 15-29 mL/min/1.73 m²) or on dialysis, as these patients have greater risk of hypocalcemia 1. This is a monitoring consideration, not a contraindication to direct transition.
The cardiovascular safety profile of romosozumab requires consideration in patients with recent myocardial infarction or stroke, but this relates to patient selection rather than washout requirements 5.